,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['bcsm', 'mbc']
asco#22, #mbc oral presentation session, destiny-b03 summary slide: no new safety signal observed with t-dxd in her+ mbc. nausea, fatigue, alopecia incidence higher with t-dxd vs t-dm1. excellent presentation by #bcsm 
Medical Oncologist, MGH, Harvard Medical School. Interested in cool science, technology, patient stories, and therapies against cancer.